Slide 1: Q1 2022 Results
Q1 2022 Results Conference call and webcast for investors and analysts 29 April 2022
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: Q1 2022 Results: conference call agenda
Q1 2022 Results: conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Dave Fredrickson EVP Oncology Business Oncology Susan Galbraith EVP Oncology R&D BioPharmaceuticals, Ruud Dobber EVP BioPharmaceuticals Business
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot Chief Executive Officer
Slide 5: Q1 2022: key updates
Q1 2022: key updates Progress against our strategic objectives Robust growth Broad-based performance Science-led innovation Strong start to the year Delivering value to patients Key developments • Total Revenue $11.4bn (+60%) • Oncology $3.6bn (+25%) • Ultomiris approval (US) ― Generalised myastheni
Slide 6: Q1 2022 Total Revenue performance
Q1 2022 Total Revenue performance Performance benefits from disease area and geographic breadth Growth across disease areas Growth across geographies Total Revenue ($m) Total Revenue ($m) 14,000 14,000 Q1 2022 | % Disease Area Q1 2022 | % Geography 12,000 12,000 10,000 Rare 10,000 Total Revenue ($m)
Slide 7: Strong 2022 outlook, poised to deliver durable growth 2025+
AstraZeneca Strong 2022 outlook, poised to deliver durable growth 2025+ Pipeline momentum Well positioned to deliver growth 2025+ Key 2022 Phase III readouts Industry-leading portfolio and pipeline H1 2022 Attractive loss of Robust lifecycle Innovative late- Strategic business exclusivity (LoE) mana
Slide 8: Financial Results
Financial Results Aradhana Sarin Chief Financial Officer
Slide 9: Q1 2022 Reported Profit and Loss
Q1 2022 Reported Profit and Loss Strong top-line growth Q1 2022 CER change % total $m % revenue Total Revenue 11,390 60 100 - Product Sales 10,980 56 96 - Collaboration Revenue 410 n/m 4 Gross margin 68.0% -7 pp Operating expenses1 7,098 52 62 - R&D expenses 2,133 26 19 - SG&A expenses 4,840 68 42 O
Slide 10: Q1 2022 Core Profit and Loss
Q1 2022 Core Profit and Loss Continued operating leverage Q1 2022 CER change % total $m % revenue Total Revenue 11,390 60 100 - Product Sales 10,980 56 96 - Collaboration Revenue 410 n/m 4 Gross margin 79.3% +4 pp Operating expenses1 5,256 29 46 - R&D expenses 2,186 36 19 - SG&A expenses 2,946 25 26
Slide 11: Reiterating 2022 guidance
Reiterating 2022 guidance Variability between quarters set to continue Key headwinds and tailwinds Delivering strong growth • Inclusion of Betalok ZOK (Seloken) in upcoming Total Revenues expected to grow by high-teens % China VBP • Continued COVID-19 impact on Oncology, R&I and Rare Disease Focused
Slide 12: Net debt and capital allocation priorities
Net debt and capital allocation priorities Improvement in cash flow from operations Net debt Capital allocation priorities • Strong investment grade credit rating • Reinvestment in the business • Value-enhancing business development 1 • Progressive dividend policy3 Net Debt/EBITDA: 3.6x Net Debt/EBI
Slide 13: Oncology
Oncology Dave Fredrickson Oncology Business Susan Galbraith Oncology R&D
Slide 14: Oncology: Q1 2022 Total Revenue
Oncology: Q1 2022 Total Revenue $3.6bn, +25%, increasing product sales and collaboration revenue 4500 4000 Q1 2022: key dynamics 3500 • Product sales $3.4bn, +18% 3000 Total Revenue ($m) 2500 • Tagrisso, Imfinzi and Lynparza double-digit Product Sales growth; Calquence and Enhertu revenues >2x Q1 20
Slide 15: New frontiers for Enhertu
New frontiers for Enhertu in HER2-low breast cancer and HER2-mut lung cancer DESTINY-Breast04 • Statistically significant and clinically Upcoming news flow meaningful improvement in both PFS and OS • Efficacy in HER2-low patients regardless of HR HER2-low BC 3L+ (DB04) | full results status • US FDA
Slide 16: Oncology: Q1 2022 R&D highlights
Oncology: Q1 2022 R&D highlights New trials start for Imfinzi in liver cancer and Tagrisso + Orpathys in lung cancer Imfinzi: EMERALD-3 Tagrisso: SAFFRON Key upcoming news flow Expanding in GI cancers Overcoming resistance mechanisms 2022 • Phase III trial in locoregional HCC • Phase III trial in ad
Slide 17: Oncology: Q1 2022 R&D highlights
Oncology: Q1 2022 R&D highlights Pioneering science previewed at AACR 2022 DDR: AZD5305 IO: MEDI5752 ADC: AZD8205 ngPARP1-sel PD-1/CTLA-4 B7-H4 TOP1i PETRA: Phase I data for next-gen PARP1- Phase I data for bispecific designed to Preclinical data from ADC targeting selective targeting tumour cell DD
Slide 18: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BioPharmaceuticals Business Mene Pangalos BioPharmaceuticals R&D
Slide 19: BioPharmaceuticals: Q1 2022 Total Revenue
BioPharmaceuticals: Q1 2022 Farxiga achieved milestone of $1bn in quarterly revenue CVRM R&I V&I $2.2bn, +18% $1.6bn, +4% $1.8bn, >6x 2,500 1,800 2,500 1,600 2,000 2,000 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 1,400 1,200 1,500 1,500 1,000 800 1,000 1,000 600 500 400 500 200 0 0 0 2
Slide 20: Emerging Markets: Q1 2022 Total Revenue
Emerging Markets: Q1 2022 Total Revenue $3.4bn, +32% including Vaxzevria Emerging Markets, +32%2 China, -6%; Ex-China EM, >2x • Oncology $897m, +19%: Tagrisso +33%, Lynparza +43% 4,000 Q1 2022 | % EM Total Revenues 3,500 • CVRM $1,025m, +10%: Farxiga +54% Total Revenue ($m) 3,000 Vaxzevria 16% • R&I
Slide 21: BioPharmaceuticals: Q1 2022 R&D highlights
BioPharmaceuticals: Q1 2022 R&D highlights Evolving cardiovascular science with eplontersen and AZD8233 AZD8233 eplontersen Key achievements Q1 2022 PCSK9 ASO ligand-conjugated antisense nirsevimab | accelerated assessment for RSV (EU) LDL-C levels 12 weeks post-first dose Saphnelo | approval for SL
Slide 22: BioPharmaceuticals: Q1 2022 R&D highlights
BioPharmaceuticals: Q1 2022 R&D highlights Scientific leadership in long-acting antibodies nirsevimab Evusheld respiratory syncytial virus COVID-19 v v Data from MEDLEY, published in NEJM1 Data from PROVENT, published in NEJM2 • 74.5% efficacy against medically-attended • 77% risk reduction against
Slide 23: Rare Disease
Rare Disease Marc Dunoyer Chief Executive Officer Alexion
Slide 24: Rare Disease: Q1 2022 Total Revenue
Rare Disease Expanded Rare Disease portfolio with addition of Koselugo in Q1 Rare Disease Q1 2022: key dynamics Total Revenue $1.7bn, +7% pro forma1 Q1 2022 2,000 1,800 • Durable growth C5 franchise (Soliris + Ultomiris), +6%1 1,600 ‒ Soliris, 0%1 strong neurology growth offset by PNH, 1,400 aHUS co
Slide 25: Durable C5 franchise
Durable C5 franchise gMG approval accelerates Ultomiris growth rate H2 2022 C5 franchise conversion Ultomiris: expanding in gMG Ultomiris vs. Soliris US pricing dynamics into complement naïve gMG patients Lower annual treatment cost per patient PNH aHUS, gMG, NMOSD Diagnosed US gMG patients +10% C.
Slide 26: Rare Disease: Q1 2022 R&D highlights
Rare Disease: Q1 2022 R&D highlights Innovative LCM and NME programs reinforce complement leadership Key upcoming news flow LCM strategy supports durable growth NMEs drive incremental growth 2022 Ultomiris | NMOSD (CHAMPION-NMO) Ultomiris ALXN2040 ALXN1720 ALXN1820 Koselugo | NF1-PN regulatory decis
Slide 27: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot Chief Executive Officer
Slide 28: Pipeline catalysts for 2022 - 2023
Pipeline catalysts for 2022 - 2023 Industry leading news flow Oncology BioPharmaceuticals Rare Disease H1 2022 H2 2022 2023 Enhertu – HER2+ breast cancer (2L) Tagrisso – EGFRm NSCLC (adjuvant) (ADAURA) (JP) Calquence – CLL (ELEVATE-TN) (JP) (DESTINY-Breast03) (US) Imfinzi +/- tremelimumab – NSCLC (1
Slide 29: AstraZeneca: 2025+
AstraZeneca: 2025+ Delivering growth through innovation Robust life-cycle Innovative Strategic business Attractive management late-stage pipeline development LoE profile Supports durable, Continued investment in Recent clinical stage US LoE for growing revenue base clinical stage pipeline business d
Slide 30: Q1 2022 Question & Answer Session
Pascal Soriot Aradhana Sarin Executive Director and Chief Executive Director and Chief Executive Officer Financial Officer Dave Fredrickson Susan Galbraith Executive Vice President, Executive Vice President, Q1 2022 Oncology Business Oncology R&D Question & Ruud Dobber Mene Pangalos Executive Vice P
Slide 31: Appendix
Appendix • Late-stage pipeline: milestones since Q4/FY 2021 • Key product performance by geography • ESG & corporate sustainability
Slide 32: Q1 2022 Product Performance: Oncology (Tagrisso, Imfinzi)
APPENDIX | Q1 2022 Product Performance Oncology Total Revenue $3.6bn; growth +25% Tagrisso Imfinzi 17% growth to $1,304m 11% growth to $599m 1,400 700 1,200 600 1,000 500 Total Revenue ($m) Total Revenue ($m) 800 400 600 300 400 200 200 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2
Slide 33: Q1 2022 Product Performance: Lynparza
APPENDIX | Q1 2022 Product Performance Oncology Total Revenue $3.6bn; growth +25% Lynparza Lynparza 17% growth to $617m (excludes Collaboration Revenue) Collaboration Revenue 700 1,000 600 800 Collaboration Revenue ($m) 500 600 Total Revenue ($m) 400 300 400 200 200 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q
Slide 34: Q1 2022 Product Performance: Calquence, Enhertu
APPENDIX | Q1 2022 Product Performance Oncology Total Revenue $3.6bn; growth +25% Calquence Enhertu 100% growth to $414m 117% growth to $86m 100 450 90 400 80 350 70 300 Total Revenue ($m) 60 Total Revenue ($m) 250 50 Total Revenue ($m) 200 40 150 30 100 20 50 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2
Slide 35: Product Performance: Cardiovascular, Renal and Metabolism
APPENDIX | Q1 2022 Product Performance BioPharmaceuticals: Cardiovascular, Renal and Metabolism Total Revenue $2.2bn; growth +18% Farxiga Brilinta Lokelma 67% growth to $1,000m 10% decline to $325m 97% growth to $63m 1,200 500 70 450 60 1,000 400 350 50 800 Total Revenue ($m) Total Revenue ($m) Tota
Slide 36: Product Performance: Respiratory & Immunology (Symbicort, Fasenra)
APPENDIX | Q1 2022 Product Performance BioPharmaceuticals: Respiratory & Immunology Total Revenue $1.6bn; growth +4% Symbicort Fasenra Stable at $674m 22% growth to $308m 900 400 800 350 700 300 600 Total Revenue ($m) 250 Total Revenue ($m) 500 200 400 150 300 100 200 100 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 37: Product Performance: Respiratory & Immunology (Breztri, Pulmicort)
APPENDIX | Q1 2022 Product Performance BioPharmaceuticals: Respiratory & Immunology Total Revenue $1.6bn; growth +4% Breztri Pulmicort 227% growth to $87m 34% decline to $217m 100 400 90 350 80 300 70 250 Total Revenue ($m) Total Revenue ($m) 60 50 200 40 150 30 100 20 50 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 38: Product Performance: Rare Disease
APPENDIX | Q1 2022 Product Performance Rare Disease Total Revenue $1.7bn; growth +7% Soliris Ultomiris Strensiq Stable at $990m 25% growth to $419m 7% growth to $208m 1,200 450 250 400 1,000 350 200 800 300 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 150 250 600 200 100 400 150 100 50 2
Slide 39: 2021 ESG Performance Highlights
Contributing to the Sustainable Development 2021 ESG Performance Highlights Goals, a universal blueprint for prosperity for people and the planet, now and into the future. Access to Environmental Ethics and healthcare protection transparency 31m+ 1 of 7 85% people reached through our access programm
Slide 40: Use of AstraZeneca slides from conference calls and webcasts
Use of AstraZeneca slides from conference calls and webcasts The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to th